Rheumnow Podcast

Individualized PsA Treatment With an IL-23i or a JAKi In Part 2 of our series on managing the complexities of PsA, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss their experience individualizing treatment for real patients with multidomain PsA and the IL-23i and JAKi data that informed their decisions. Sponsored by AbbVie Medical Affairs + Health Impact. https://rheumnow.com/therapeutic-update/individualized-psa-treatment-il-23i-and-jaki
After posting, if you could log into spodity studio, and turn off transcripts, comments, and chapters, that would be great. If you don't have time to do this, let me know and I can log...

Every day, every month, rheumatology publishes news and reports on JAK inhibitors, IL-17s, IL-23s, lupus, myositis, and scleroderma – all which could change how you practice dermatology. I'm Jack Cush from RheumNow, and This is Derm on RheumNow.

This month’s podcast will Scratch the surface and find new drugs for dermographism, Hidradenitis, SLE, DLE & PsA. Probiotics loseout to placebo in PsA and Obesity sinks psoriasis biologics.
This month: 
- The FDA is reviewing Sun Pharma’s tildrakizumab (Ilumya), an IL-23 inhibitor, for use in active psoriatic arthritis, with an October 29, 2026, action (PDUFA) date. Decisio...

Dr. Cush reviews the news and journal reports from this past week on RheumNow.  This week on the podcast – hopeful guidelines for PMR, certainty about good & bad beverages in gout; Mixed results in Sjogrens, non Lupus drugs saves Lupus lives and big hips sinks ships in Psoriatic arthritis.

Listen to leading rheumatology and dermatology experts for an engaging discussion on the evolving landscape of Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE).

Drawing on recent RheumNow survey findings, our expert panel explores real-world challenges in lupus assessment and management, clinical decision-making, disease activity evaluation, current treatment strategies, and emerging therapeutic approaches. Gain valuable perspectives on advances in lupus care, persistent unmet needs, and opportunities to improve patient outcomes.

Expert Panelists:

Victoria P. Werth, MD

Joseph F. Merola, MD

Maria Dall'Era, MD

Moderator: Jack Cush...

Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint; twice the cryptococcus risk in JAKs?; Myositis and Scleroderma; and a Sjögren’s patient with early damage has a greater than 2-fold risk of lymphoma. Double trouble week on the RheumNow podcast.

Dr. Jack Cush reviews this weeks news from RheumNow.com -- including placebo trumps controversial therapies,  the dynamics of disease activity, fuze the big toe, and patients don’t appreciate being told “its all in your head”!

On this weeks podcast Dr. Jack Cush reviews the news - Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age old messages for old age patients.

Dr. Saakshi Khattri hosts dermatologist Dr. Ahmad Amin and gastroenterologist Dr. Joshua Steinberg to discuss multidisciplinary care in PsA and other immune-mediated inflammatory diseases. Learn how signals in the skin and gut may prompt the need for collaboration across specialties to support better patient outcomes that extend beyond the joints. Sponsored by AbbVie Medical Affairs + Health Impact. https://rheumnow.com/therapeutic-update/psa-beyond-joints-rheum-derm-and-gastro-perspectives

Dr, Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Dr. Lourdes Perez-Chada Sleep and Obesity: The Role of Sleep in Weight Management: https://youtu.be/3gcJtb5gjI4
Dr. Alexis Ogdie & Dr. Anastassia Amaro Physician Perspective: Talking to Patients Regarding Obesity: https://youtu.be/6-EVOTiUKio

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors.

Features Dr. Jack Cush, Editor at RheumNow.com.

Show Notes:

FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw

Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 co...

In the final webinar in this series, we move beyond the medication to explore what comprehensive obesity care can look like in rheumatology practice. Experts will discuss practical approaches to patient conversations, lifestyle support and referrals, overcoming weight bias and barriers to care, and building a sustainable care model that leverages the broader healthcare team, technology, and current clinical guidelines.
Speakers: Dr. Alvin Wells Dr. Alexis Ogdie Stacie Ireland, NP Dr. Guada Respicio Dr. Jack Cush

Dr. Catherine Bakewell 'Pharmacologic Treatment of Obesity': https://youtu.be/K8o0ZnqySZA
Dr. Larissa McGarrity 'Psychology of Health Behavior Change in Obesity': https://youtu.be/v-rGrpjqh24
Dr. Elena Philippou 'Nutrition, Weight Management and Rheumatic Disease': https://youtu.be/2EOpgsS-EfA

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Daric Mueller (PA-C) RA, IBD and Frank's Sign: https://youtu.be/guRvytT9NW4
Dr. Bella Mehta Weight Loss Changed the Course of Rheumatoid Arthritis: https://youtu.be/hD-BydV8HYE
Dr. Eric Dein Treat to Target Obesity: https://youtu.be/zoohn5XfES4

In this webinar, experts discuss the rapidly evolving landscape of obesity treatment, from lifestyle interventions and bariatric surgery to the latest incretin-based therapies and emerging approaches to precision management. Faculty will share practical guidance on selecting appropriate treatments, optimizing GLP-1/GIP therapy, navigating safety, cost and compounding concerns, and providing comprehensive care that considers issues such as sarcopenia and bone health. Speakers: Dr. Juliana Simonetti Dr. Grace Wright Dr. Jack Cush (moderator) Dr. Philip Mease

Dr. Jack Cush 'Introducing Weightloss': https://youtu.be/-CDsmyaCVJQ
Dr. Derin Karacabeyli 'Building A Multidisciplinary Program for Obesity and Arthritis Management': https://youtu.be/42Ac1xmXn4k

Dr Juliana Simonetti 7 Dr. Philip Mease 'What Are the Four Pillars of Obesity Management?': https://youtu.be/TwhlkRtsjtA

Dr. Richard Conway Bariatric Surgery 'Curing' Arthritis?: https://youtu.be/W2-0RkyGqcc
Dr. David Liew Managing Muscle and Fat Loss with GLP-1s: https://youtu.be/fLCDLuJGyPA
Daric Mueller (PA-C) GLP-1s and History of Thyroid Cancer?:https://youtu.be/H_UlthPGN6Y
Dr. Bella Mehta How Weight Loss Changes the Course of Knee Osteoarthritis: https://youtu.be/Jg0hflvIMEo

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Dr. Antoni Chan The Weight Behind the Delay in Diagnosis: https://youtu.be/-gxaFidWRw0 
Dr. Mrinalini Dey Obesity: Escalate or Reassess?: https://youtu.be/Y6f_Qt5snMI
Dr. Michael Putman Managing Obesity: By PCP or Rheumatologist?: https://youtu.be/zASyKJECfiM

Explore the complex relationship between obesity, inflammation, and rheumatic disease—and how excess adiposity may influence disease development, severity, treatment response, and patient outcomes.

In this expert-led discussion, leading clinicians and researchers examine how obesity can accelerate inflammatory and autoimmune rheumatic disease through metabolic, biomechanical, and immunologic pathways.

The panel explores the biology of adipose tissue and its role in systemic inflammation, including how obesity affects disease risk and progression, response to rheumatologic therapies, and the potential for weight loss and other interventions to reduce inflammation and improve clinical outcomes.

Expert Faculty:
• Juli...

Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis.

The Obesity Journal Club explores the TOGETHER PsA and STEP 9 trials and what emerging evidence tells us about the relationship between obesity, weight loss, and rheumatic disease. Authors of the papers and experts will discuss the results of these trials, discuss how we consider obesity as both a comorbidity and part of the disease course, and share practical strategies for addressing obesity in everyday rheumatology practice.
Speakers: Dr. Philip Mease Dr. Tom Appleton Dr. Jack Cush (moderator)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control.

Join Amanda Mixon, PA-C, for a practical look at the role of the rheumatology advanced practice provider (APP) in recognizing and managing interstitial lung disease (ILD).

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects.

Features Dr. Jack Cush, Editor at RheumNow.com.

Show Notes:
Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be 15 million (4.6% US population); 34% have 2+ AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://buff.ly/fYgRfZ0

POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tes...

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update. Sponsored by Johnson & Johnson Medical Affairs

Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.

Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.

Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com

Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026. Learn how those findings impact their clinical decision-making. Sponsored by AbbVie Medical Affairs + Health Impact

Dr. Jack Cush Obesity & Gout

Dr. Tony Merriman Genome-Wide Association Studies in Gout

Dr. Lisa Stamp Gout Management in Patients with Chronic Kidney Disease

Dr. Mark Fisher Gout & Mortality

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Dr. Sheila Reyes: QD Clinic: The Highs and Lows of a Woman with Gout
 
Dr. Jack Cush QD319 A Watched Tophus Never Resolves 

Dr. Eric Dein QD316: Addressing Severe Gout Flares 

Dr. Janet Pope QD Clinic: RA Mimics — Two Cases That Turned Out to Be Gout 

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects.

Features Dr. Jack Cush, Editor at RheumNow.com.
Show Notes:

- 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72

Systemic sclerosis metanalysis of 31 studies (32,134 pt...

New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)

Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology

Dr. Nicola Dalbeth Outcomes of Tophaceous Gout 

Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout

Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?

Dr. John Fitzgerald Gout & Metabolic syndrome

Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients

Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity